NCT00397982 2017-06-09
Mel47
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
5 trialsNCT00022464 2015-06-08
CCI-779 in Treating Patients With Metastatic Melanoma
City of Hope Medical Center
Phase 2 Completed
NCT01851408 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00281957 2014-05-20
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01166126 2014-05-15
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
National Cancer Institute (NCI)
Phase 2 Terminated